SkinBioTherapeutics PLC represents values of innovation, scientific excellence, and commitment to improving skin health. The company focuses on developing unique microbiome-based treatments that address various skin conditions. Its corporate philosophy revolves around leveraging cutting-edge research and technology to deliver safe and effective solutions for dermatological needs. SkinBioTherapeutics PLC aims to provide individuals with quality products that enhance skin wellness and restore confidence. By continuously exploring the potential of the skin microbiome, the company aims to transform the field of skincare and contribute to a healthier future for all.

SkinBioTherapeutics PLC is primarily present in the United Kingdom.

SkinBioTherapeutics PLC has achieved several significant milestones. These include successful completion of its Phase I clinical trial for its flagship product, SkinBiotix®, which demonstrated excellent safety and tolerability. Additionally, the company has entered into various strategic collaborations with renowned industry partners, such as Croda International PLC, to enhance the development and commercialization of its products. SkinBioTherapeutics has also gained recognition through numerous awards and grants, emphasizing its commitment to innovation and excellence in skincare solutions. As a leading skincare company, SkinBioTherapeutics PLC continues to make remarkable strides in advancing the field of microbiome-based therapeutics for healthier and rejuvenated skin.

SkinBioTherapeutics PLC is a renowned company specializing in the development of innovative products for the cosmetic and healthcare industries. Established in 2016, SkinBioTherapeutics PLC has quickly gained recognition for its cutting-edge research and commitment to improving skin health. The company focuses on harnessing the skin's natural biofilms to develop groundbreaking solutions for conditions like acne, psoriasis, and aging skin. With a team of expert scientists and researchers, SkinBioTherapeutics PLC has made significant strides in understanding the skin microbiome and its impact on overall skin health. The company's dedication to scientific excellence and customer satisfaction has solidified its position as a leader in the industry.

The main competitors of SkinBioTherapeutics PLC in the market are companies like Procter & Gamble Co., Unilever PLC, L'Oréal SA, Johnson & Johnson, and Estée Lauder Companies Inc. These companies also operate in the skincare and dermatology industry, offering a range of products and services that may compete with SkinBioTherapeutics PLC.

SkinBioTherapeutics PLC primarily operates in the healthcare and pharmaceutical industries.

The business model of SkinBioTherapeutics PLC focuses on the research, development, and commercialization of microbiome-based skincare products. By leveraging the potential of the skin's microbiome, the company aims to innovate and deliver scientifically proven skin health solutions. SkinBioTherapeutics PLC utilizes its proprietary SkinBiotix technology to develop and formulate microbiome-targeted products that have the potential to improve various skin conditions. With a strong emphasis on scientific research and collaboration, the company aims to address the growing demand for solutions that promote healthy skin. Through strategic partnerships and continuous innovation, SkinBioTherapeutics PLC aims to establish itself as a leader in the microbiome-based skincare industry.

SkinBioTherapeutics KGV ir -7,62.

SkinBioTherapeutics KUV ir 23,72.

AlleAktien kvalitātes vērtējums SkinBioTherapeutics ir 3/10.

gaidāmā SkinBioTherapeutics apgrozījums ir 1,11 milj. GBP.

gaidāmā SkinBioTherapeutics peļņa ir -3,46 milj. GBP.

The SkinBioTherapeutics PLC is a company specializing in biotech products for skincare. Its business model is based on the development of products that are based on probiotics and other natural ingredients and treat and prevent skin conditions. The company operates in three main divisions: research and development, manufacturing, and distribution. In the research department, new products are developed targeting specific dermatoses. The company has focused its research on probiotics and develops products based on the microorganisms on the skin. Manufacturing takes place in specially equipped laboratories to ensure strict quality standards. SkinBioTherapeutics' flagship product is the SkinBiotix program. This consists of a range of products based on the skin's flora and developed to treat various skin conditions. The program offers solutions for skin conditions such as acne, eczema, and rosacea. The company also has a partnership with Winclove Probiotics to develop a product called AxisBiotix. This product is intended to support microbial diversity in the gut, which can have a positive effect on the skin. The idea behind this is that many skin problems are related to impaired gut function. SkinBioTherapeutics also has the potential to operate in the dermocosmetics sector. The company can bring its products to the cosmetic market based on its research and development of probiotic products. The brand "Synbiotix" has already been introduced and is intended to offer a wider range of skincare products. The company also plans to make its technology platform, SkinBiotix, available to other companies through licensing agreements. The technology is innovative and unique and has the potential to change the way we look at skincare products. SkinBioTherapeutics positions itself as a company that sets itself apart from other skincare companies by being based on microbiology and science rather than fashion trends or pseudoscience. The company emphasizes the scientific approach and the fact that its products are based on the skin's flora, which means they are more natural and effective. SkinBioTherapeutics' business model is based on innovative research and development and the use of probiotics in skincare products. The company offers a wide range of products based on the SkinBiotix technology targeting a variety of skin conditions. The company also plans to make its technology platform available to other companies and expand its presence in the cosmetic market.

SkinBioTherapeutics izmaksā dividendes 0 GBP, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt SkinBioTherapeutics vai uzņēmums nedod dividendes.

SkinBioTherapeutics ISIN ir GB00BF33H870.

SkinBioTherapeutics WKN ir A2DPW8.

SkinBioTherapeutics simbols ir SBTX.L.

Pēdējo 12 mēnešu laikā SkinBioTherapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos SkinBioTherapeutics plāno maksāt dividendes 0 GBP apmērā.

SkinBioTherapeutics pašreizējā dividendu rentabilitāte ir .

SkinBioTherapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

SkinBioTherapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 GBP. Tas atbilst dividendes ražībai 0 %.

SkinBioTherapeutics tiek piešķirts nozarei "Necikliskais patēriņš".

Lai saņemtu pēdējo dividendu SkinBioTherapeutics apmērā 0 GBP, kas tika izmaksāta 23.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 23.11.2024..

Pēdējās dividendes izmaksa notika 23.11.2024..

Gadā 2023, SkinBioTherapeutics izmaksāja 0 GBP dividendes.

SkinBioTherapeutics dividendes tiek izmaksātas GBP.